Children’s preferences among six novel moxifloxacin and linezolid-dispersible tablet formulations
IJTLD Open · 2025-04 · 2 (4) · 208-216
DOI: 10.5588/ijtldopen.24.0546 ↗Kurz gefasst
Fachartikel in der Zeitschrift IJTLD Open, online erschienen am 01.04.2025. Verfasst von G Hoddinott und 13 weiteren Autor:innen. Beteiligte Einrichtung: Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, Sout…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
BACKGROUND Moxifloxacin (MFX) and linezolid (LZD) are key components of rifampicin-resistant TB treatment regimens. Currently, available dispersible tablet formulations of both drugs have poor palatability in children. We evaluated children’s preferences for more child-friendly formulations from two generic manufacturers. METHODS This was a randomised, cross-sectional ‘swish-and-spit’ taste panel study at two sites in South Africa. Each manufacturer created three flavour-blend variants for each drug. Healthy child volunteers 5–17 years old were sampled stratified by age, sex, and ethnic group and completed a preference rank-ordering and five acceptability 5-point Likert scales. We explored the blends’ acceptability using summary, comparative, and ranking statistics. RESULTS Ninety-seven and 96 children contributed data for the MFX and LZD drug blends, respectively. For both manufacturers’ MFX blends, the Friedman test showed children had a statistically significant preference for novel options over the Existing blend (Q(2) = 24,937; P < 0.001, and Q(2) = 21.213; P < 0.001, respectively). Even the most preferred MFX blend had sub-optimal acceptability, especially for one manufacturer. Children did not have a clear preference for both manufacturers’ LZD blends. These findings were not influenced by age, sex, or ethnic group. CONCLUSION Children across a broad age spectrum can provide meaningful input on the palatability preferences of TB drug formulations. Novel MFX formulation blends were recommended for development, but acceptability remains suboptimal.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
- School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
- THINK Tuberculosis and HIV Investigative Network (RF) NPC, Durban, South Africa.
- Global Alliance for TB Drug Development (TB Alliance), New York, NY, USA.
- Department of Pediatrics, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
Zitieren
APA
Hoddinott, G., Draper, H. R., Vanqa, N., Myeni, S., Staples, S., Sachs, T., Raffique, M., Tshethu, N., Palmer, M., Viljoen, L., Inabathina, K., Taneja, R., Hesseling, A. C., & Garcia-Prats, A. J. (2025). Children’s preferences among six novel moxifloxacin and linezolid-dispersible tablet formulations. IJTLD Open, 2(4), 208-216. https://doi.org/10.5588/ijtldopen.24.0546
Vancouver
Hoddinott G, Draper HR, Vanqa N, Myeni S, Staples S, Sachs T, et al. Children’s preferences among six novel moxifloxacin and linezolid-dispersible tablet formulations. IJTLD Open. 2025;2(4):208-216. doi:10.5588/ijtldopen.24.0546
BibTeX
@article{Hoddinott2025,
author = {Hoddinott, G and Draper, H R and Vanqa, N and Myeni, S and Staples, S and Sachs, T and Raffique, M and Tshethu, N and Palmer, M and Viljoen, L and Inabathina, K and Taneja, R and Hesseling, A C and Garcia-Prats, A J},
title = {Children’s preferences among six novel moxifloxacin and linezolid-dispersible tablet formulations},
journal = {IJTLD Open},
year = {2025},
volume = {2},
number = {4},
pages = {208--216},
doi = {10.5588/ijtldopen.24.0546}
}
EUVIMED